FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164666147> ?p ?o ?g. }

• W2164666147 endingPage "5526" @default.
• W2164666147 startingPage "5517" @default.
• W2164666147 abstract "Abstract Purpose: Ameloblastoma is an odontogenic neoplasm whose overall mutational landscape has not been well characterized. We sought to characterize pathogenic mutations in ameloblastoma and their clinical and functional significance with an emphasis on the mitogen-activated protein kinase (MAPK) pathway. Experimental Design: A total of 84 ameloblastomas and 40 non-ameloblastoma odontogenic tumors were evaluated with a combination of BRAF V600E allele–specific PCR, VE1 immunohistochemistry, the Ion AmpliSeq Cancer Hotspot Panel, and Sanger sequencing. Efficacy of a BRAF inhibitor was evaluated in an ameloblastoma-derived cell line. Results: Somatic, activating, and mutually exclusive RAS–BRAF and FGFR2 mutations were identified in 88% of cases. Somatic mutations in SMO, CTNNB1, PIK3CA, and SMARCB1 were also identified. BRAF V600E was the most common mutation, found in 62% of ameloblastomas and in ameloblastic fibromas/fibrodentinomas but not in other odontogenic tumors. This mutation was associated with a younger age of onset, whereas BRAF wild-type cases arose more frequently in the maxilla and showed earlier recurrences. One hundred percent concordance was observed between VE1 immunohistochemistry and molecular detection of BRAF V600E mutations. Ameloblastoma cells demonstrated constitutive MAPK pathway activation in vitro. Proliferation and MAPK activation were potently inhibited by the BRAF inhibitor vemurafenib. Conclusions: Our findings suggest that activating FGFR2–RAS–BRAF mutations play a critical role in the pathogenesis of most cases of ameloblastoma. Somatic mutations in SMO, CTNNB1, PIK3CA, and SMARCB1 may function as secondary mutations. BRAF V600E mutations have both diagnostic and prognostic implications. In vitro response of ameloblastoma to a BRAF inhibitor suggests a potential role for targeted therapy. Clin Cancer Res; 20(21); 5517–26. ©2014 AACR." @default.
• W2164666147 created "2016-06-24" @default.
• W2164666147 creator A5005952114 @default.
• W2164666147 creator A5018984989 @default.
• W2164666147 creator A5019959500 @default.
• W2164666147 creator A5041898934 @default.
• W2164666147 creator A5042044822 @default.
• W2164666147 creator A5051202793 @default.
• W2164666147 creator A5066152690 @default.
• W2164666147 creator A5086113297 @default.
• W2164666147 date "2014-10-30" @default.
• W2164666147 modified "2023-10-17" @default.
• W2164666147 title "Activating <i>FGFR2–RAS–BRAF</i> Mutations in Ameloblastoma" @default.
• W2164666147 cites W1486085706 @default.
• W2164666147 cites W1520577253 @default.
• W2164666147 cites W1524280083 @default.
• W2164666147 cites W1593752706 @default.
• W2164666147 cites W1594815607 @default.
• W2164666147 cites W1965431780 @default.
• W2164666147 cites W1973335462 @default.
• W2164666147 cites W1985035689 @default.
• W2164666147 cites W1989121777 @default.
• W2164666147 cites W1994409204 @default.
• W2164666147 cites W1994620081 @default.
• W2164666147 cites W1996429288 @default.
• W2164666147 cites W2000381516 @default.
• W2164666147 cites W2003811411 @default.
• W2164666147 cites W2008599012 @default.
• W2164666147 cites W2013831759 @default.
• W2164666147 cites W2015940023 @default.
• W2164666147 cites W2022306295 @default.
• W2164666147 cites W2041653784 @default.
• W2164666147 cites W2048765718 @default.
• W2164666147 cites W2052679253 @default.
• W2164666147 cites W2068127752 @default.
• W2164666147 cites W2070841378 @default.
• W2164666147 cites W2070871778 @default.
• W2164666147 cites W2075790601 @default.
• W2164666147 cites W2082812812 @default.
• W2164666147 cites W2084243966 @default.
• W2164666147 cites W2092929111 @default.
• W2164666147 cites W2095439711 @default.
• W2164666147 cites W2096055270 @default.
• W2164666147 cites W2099019742 @default.
• W2164666147 cites W2099780734 @default.
• W2164666147 cites W2102584939 @default.
• W2164666147 cites W2114219024 @default.
• W2164666147 cites W2125703895 @default.
• W2164666147 cites W2141416577 @default.
• W2164666147 cites W2144040817 @default.
• W2164666147 cites W2154170543 @default.
• W2164666147 cites W2164185692 @default.
• W2164666147 cites W2170410370 @default.
• W2164666147 cites W2330934614 @default.
• W2164666147 cites W4230628886 @default.
• W2164666147 doi "https://doi.org/10.1158/1078-0432.ccr-14-1069" @default.
• W2164666147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24993163" @default.
• W2164666147 hasPublicationYear "2014" @default.
• W2164666147 type Work @default.
• W2164666147 sameAs 2164666147 @default.
• W2164666147 citedByCount "198" @default.
• W2164666147 countsByYear W21646661472014 @default.
• W2164666147 countsByYear W21646661472015 @default.
• W2164666147 countsByYear W21646661472016 @default.
• W2164666147 countsByYear W21646661472017 @default.
• W2164666147 countsByYear W21646661472018 @default.
• W2164666147 countsByYear W21646661472019 @default.
• W2164666147 countsByYear W21646661472020 @default.
• W2164666147 countsByYear W21646661472021 @default.
• W2164666147 countsByYear W21646661472022 @default.
• W2164666147 countsByYear W21646661472023 @default.
• W2164666147 crossrefType "journal-article" @default.
• W2164666147 hasAuthorship W2164666147A5005952114 @default.
• W2164666147 hasAuthorship W2164666147A5018984989 @default.
• W2164666147 hasAuthorship W2164666147A5019959500 @default.
• W2164666147 hasAuthorship W2164666147A5041898934 @default.
• W2164666147 hasAuthorship W2164666147A5042044822 @default.
• W2164666147 hasAuthorship W2164666147A5051202793 @default.
• W2164666147 hasAuthorship W2164666147A5066152690 @default.
• W2164666147 hasAuthorship W2164666147A5086113297 @default.
• W2164666147 hasBestOaLocation W21646661471 @default.
• W2164666147 hasConcept C104317684 @default.
• W2164666147 hasConcept C105702510 @default.
• W2164666147 hasConcept C121608353 @default.
• W2164666147 hasConcept C122246415 @default.
• W2164666147 hasConcept C134305767 @default.
• W2164666147 hasConcept C13514818 @default.
• W2164666147 hasConcept C142724271 @default.
• W2164666147 hasConcept C204232928 @default.
• W2164666147 hasConcept C2775876115 @default.
• W2164666147 hasConcept C2776131300 @default.
• W2164666147 hasConcept C2776470698 @default.
• W2164666147 hasConcept C2777658100 @default.
• W2164666147 hasConcept C2781230642 @default.
• W2164666147 hasConcept C2994587330 @default.
• W2164666147 hasConcept C501734568 @default.
• W2164666147 hasConcept C502942594 @default.
• W2164666147 hasConcept C54355233 @default.

• next